MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Outlook Arena
- Mar 4, 2002 - Knoll Pharma: Consolidating operations
Knoll Pharma: Consolidating operations
Knoll Pharma has declared a 33% drop in net profits for the year ended November'01. The company has changed its accounting year from December to November year ending. Hence the latest results are not strictly comparable as this year of the company was for a period of 11 months.
| (Rs m) | FY01 | FY02 | % Change |
| Sales | 3,333 | 3,246 | -2.6% |
| Other Income | 310 | 166 | -46.5% |
| Expenditure | 2,860 | 2,720 | -4.9% |
| Operating Profit (EBDIT) | 473 | 526 | 11.1% |
| Operating Profit Margin (%) | 14.2% | 16.2% | 14.1% |
| Interest | 15 | 1 | -91.8% |
| Depreciation | 53 | 45 | -15.9% |
| Profit before Tax | 715 | 646 | -9.7% |
| Extraordinary Income | 132 | - | |
| Tax | 125 | 159 | 27.4% |
| Profit after Tax/(Loss) | 722 | 487 | -32.6% |
| Net profit margin (%) | 21.7% | 15.0% | |
| No. of Shares (eoy) (m) | 16 | 16 | |
| Diluted Earnings per share* | 44.6 | 30.1 | |
| P/E (at current price) | 10.2 | ||
| (*- annualised) | |||
On an annualised basis however, sales have registered a growth of more than 6%. Operating margins showed a good improvement of 200 basis points. The jump in operating margins was on the back of upward revision of four formulations of Insulin injection in March. Insulin Vial prices have increased by 22% - 25% since then. Insulin is the biggest revenue churner for Knoll where the company has a market share of close to 60%. Other income was on account of sale of mutual fund units of Rs 58 m and dividend received from wholly owned subsidiary.
Knoll Pharma seems to be in a consolidation mood. The company is in the process of taking shareholder permission to sell/divest its manufacturing unit at Pune and for the buyback of its shares. It plans to sell its plant as a going concern. It is proposing buyback of shares at a maximum price of Rs 350 per share. The markets however, seem to have sensed the proposal ahead of time, with the stock price appreciating more than 30% in last two months.
Knoll Pharma has also proposed 100% dividend i.e. Rs 10 per share. The stock currently trades (cum dividend) at Rs 308. Considering, the dividend the stock still trades at 15% discount to the buyback price proposed by the company.The buyback however, is dependent on shareholder's approval.
More Views on News
ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)
Aug 18, 2020 | Updated on Aug 18, 2020For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsMost Popular
A Critical Update on the Market (Fast Profits Daily)
Mar 30, 2021In this video, I'll tell you why I am recommending caution in the market at this time.
My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)
Mar 31, 2021A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
My Stock Trading Strategy (Fast Profits Daily)
Mar 31, 2021In this video I'll show you exactly how I go about picking stocks for trading.
What You Need to Find Hundred Baggers (Profit Hunter)
Mar 30, 2021100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
MoreOUR TOP 5 IDEAS
- India's Revival: A Once-in-a-generation Wealth Making Opportunity
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
ABBOTT INDIA SHARE PRICE
Apr 12, 2021 09:36 AM
TRACK ABBOTT INDIA
- Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ABBOTT INDIA
ABBOTT INDIA - TEVA PHARMA COMPARISON
COMPARE ABBOTT INDIA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "Knoll Pharma: Consolidating operations". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!